PCM
UBX

Prelude Capital Management’s Unity Biotechnology UBX Stock Holding History

Prelude Capital Management’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-967
Closed -$84K – 2370
2020
Q2 		$84K Buy
+967
New +$71.7K ﹤0.01% 1007

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Prelude Capital Management's UBX Position: Q3 2020 in Review

Prelude Capital Management sold out of Unity Biotechnology (UBX) in Q3 2020, closing a stake of 967 shares — an estimated $84K sold.

Prelude Capital Management first reported a position in UBX in Q2 2020 and held it in 1 quarter. The position peaked at $84K in Q2 2020. 79 funds tracked by Wall St. Rank hold UBX as of Q3 2020.

  • Prelude Capital Management reported no remaining Unity Biotechnology position as of Q3 2020 after selling out during the quarter.
  • Prelude Capital Management sold 967 Unity Biotechnology shares in Q3 2020, an estimated $84K.
  • Prelude Capital Management first reported a position in Unity Biotechnology in Q2 2020 and held it in 1 quarter.
  • Prelude Capital Management's Unity Biotechnology position peaked at $84K in Q2 2020.
  • 79 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2020.

Based on Prelude Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.